News Releases

Nov 30, 2022 Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema
Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life REDWOOD CITY, Calif. & TOKYO --(BUSINESS WIRE)--Nov. 30, 2022-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally
Nov 16, 2022 Pulmonx to Present at the 34th Annual Piper Sandler Healthcare Conference
REDWOOD CITY, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 34th Annual Piper Sandler Healthcare
Nov 04, 2022 Pulmonx to Participate at Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York.
Nov 03, 2022 Pulmonx Reports Third Quarter 2022 Financial Results
REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter ended September 30, 2022.
Oct 20, 2022 Pulmonx to Report Third Quarter 2022 Financial Results on November 3, 2022
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2022 after the close of trading on Thursday,
Sep 04, 2022 CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema
The reported data suggest that patients with collateral ventilation may be able to undergo successful treatment with Zephyr Endobronchial Valves following closure of collateral air channels with the AeriSeal System REDWOOD CITY, Calif. & BARCELONA, Spain --(BUSINESS WIRE)--Sep.
Aug 24, 2022 Pulmonx to Present at Upcoming September Investor Conferences
REDWOOD CITY, Calif. --(BUSINESS WIRE)--Aug. 24, 2022-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in fireside chats at two upcoming investor conferences.
Aug 02, 2022 Pulmonx Reports Second Quarter 2022 Financial Results
REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter ended June 30, 2022.
Jul 27, 2022 Pulmonx to Present at the Canaccord Genuity 42nd Annual Growth Conference
REDWOOD CITY, Calif. --(BUSINESS WIRE)--Jul. 27, 2022-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference in Boston .
Jul 19, 2022 Pulmonx to Report Second Quarter 2022 Financial Results on August 2, 2022
REDWOOD CITY, Calif. --(BUSINESS WIRE)--Jul. 19, 2022-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Tuesday,
Displaying 1 - 10 of 16
Print Page
Email Alerts
Contact IR
RSS Feeds